correlation of trop-2 expression with clinicopathological characteristics and outcome in tnbc
Published 2 years ago • 654 plays • Length 3:44Download video MP4
Download video MP3
Similar videos
-
2:57
efficacy of sacituzumab govitecan in muc by trop-2 expression
-
2:16
efficacy of sacituzumab govitecan by trop-2 expression in patients with muc
-
1:17
correlation between trop2 and pcr in patients with her2-positive early breast cancer
-
7:16
e-cadherin inactivation by trop-2 drives metastases in tnbc
-
2:14
clinical and molecular characteristics of her2-low/zero early stage triple-negative breast cancer
-
4:25
ascent: sacituzumab govitecan shows promise in mtnbc patients
-
1:34
sacituzumab govitecan effective for hr metastatic breast cancer regardless of trop-2 status
-
4:38
2nd interim analysis of os from tropics-02: sg in hr /her2- breast cancer
-
1:23
antibody-drug conjugates for the treatment of breast cancer
-
1:36
efficacy of datopotamab deruxtecan, a trop2 adc, in ansclc
-
1:36
is her2-low a distinct subtype of breast cancer?
-
1:16
her2-low expression in breast cancer
-
1:29
the genetics of breast cancer complete response
-
1:12
correlation between pregnancy and breast cancer outcomes
-
21:36
treatment planning for triple negative breast cancer | 2022 evolution conference
-
2:00
an overview of the geparsepto trial in luminal, triple-negative, and her2 breast cancer
-
16:58
assessing immune biomarkers of response to anthracyclines in breast cancer
-
1:30
treatment response assessment in melanoma and the challenge of pseudoprogression with immunotherapy
-
4:46
entinostat, nivolumab and ipilimumab in advanced her2-negative breast cancer